Chronos Archive seal

Review checklist: Marie Curie (HR-ET013)

All records · Back to the record · Dossier (sources.md) · Terminology · Report a problem · Comments

Everything a reviewer needs to judge, gathered from the record. Release status: draft.

Review status

ReviewStatusReviewerDateNotes
schema validationnot_startedRun scripts/build.ps1 -Conformance.
clinical reviewnot_startedAwaiting clinician review.
provenance reviewnot_startedNobel biography, AIP exhibit pages, Physics Today, and a Spanish ophthalmology history paper logged; the Musée Curie site was not reviewed.
safe messaging reviewnot_startedDeath recorded without graphic detail; PHQ-2 negative at both screens.

Judgment calls (dossier editorial resolutions)

  1. Index age. The modern episode presents Curie at 66, her age when she fell ill in May 1934. The index visit is May 11, 2026; the true-date frame places all four visits in May and June 1934, before her death on July 4, 1934. Past medical history and family history include only events before May 1934.
  2. Modern diagnosis. The contemporary diagnosis of aplastic pernicious anemia is documented (D). The synthetic episode makes it severe aplastic anemia confirmed by a hypocellular marrow, coded ICD-10-CM D61.2 (aplastic anemia due to other external agents). The radiation cause is an interpretation (R, probable) and the occupational exposure is coded separately (Z57.1). The marrow findings, counts, and treatment are S. The specialist chooses standard immunosuppressive therapy because an immune mechanism cannot be excluded.
  3. Cataracts. The 1920 double cataract and four operations from 1923 to 1930 are D; the radiation interpretation is R. Because the operations precede the index age, the modern eye problem is posterior capsule opacification after earlier surgery (H26.491), treated with YAG laser capsulotomy. Modern lens implants did not exist in the 1920s; the modern eye history is synthetic.
  4. Finger burns. The documented burns are linked to a synthetic chronic radiodermatitis problem (L58.1).
  5. Nationality. Recorded as “Polish / French,” matching the roster.
  6. Not used. The Musée Curie site was not reviewed. The name of the sanatorium (Sancellemoz, Passy) appears in secondary summaries that were not verified from a logged source; the Nobel biography says only that she died in Savoy. Her surgeon’s name and the dates of the individual cataract operations were not found. Her father’s death and her daughter Irène’s later leukemia were not used. Her recollection of profound low mood after her mother’s death was not recorded as a diagnosis.
  7. Focused visits. The three follow-ups (the hematology consultation and the three- and six-week primary care reviews) are documented as focused visits on the BSH aplastic anaemia guideline, with the CMID anemia monograph (symptom assessment, restrictive transfusion threshold) and cataract monograph (comprehensive eye examination and functional vision assessment) and the AAO cataract Preferred Practice Pattern for the capsulotomy. No visit was added, and nothing anticipates her death in the true frame. Synthetic findings introduced: bruises and lower-leg petechiae, a flow murmur, the hazy and then clear right red reflex, completion of the four-day antithymocyte globulin course, and full adherence. Protocol deviations recorded instead of invented results: no pre-treatment ALT before eltrombopag; no pre-treatment viral serology in the record; no cyclosporine trough level in the record at either review, with the creatinine rise from 0.78 to 1.02 mg/dL prompting a dose review; weekly blood counts missed between visits, and kidney function, potassium, and ALT checked at three weeks rather than every two; no antibacterial or antifungal prophylaxis while neutrophils were at or below 0.5, which the guideline leaves to local policy; and no post-laser pressure reading after the capsulotomy. Later results showed no harm from any of them by the six-week visit.
  8. Consultation. The hematology referral and consultation are synthetic and written for this case. Dr. Brenner's examination repeats the focused note of the consultation day, and his recommendations agree with the record: the four-day horse antithymocyte globulin course, cyclosporine, eltrombopag, and acyclovir from that day; irradiated blood products; inactivated vaccines only; and weekly counts with kidney function, potassium, and ALT every two weeks. Where the focused visits record deviations, the consultant recommends the step and the later notes show it was late or never done: ALT and viral serology with the next blood draw (ALT first appears three weeks later; no serology ever appears), a first cyclosporine trough within the first weeks (none appears), and weekly counts through the hematology day unit (none appear between visits). No result is stated for any of them. Judgment calls: the consultant records that treatment began without ALT or viral serology because neutrophils were 0.4 and platelets 15; antibacterial and antifungal prophylaxis are not started and are left to local policy, matching the recorded gap; and platelet support is described only as following the hematology unit's protocol during the antithymocyte globulin course and given for bleeding afterward, so no platelet transfusion or threshold is invented. Nothing in the consultation speaks of prognosis or anticipates her death in the true frame.
  9. Curie died in 1934, so the recent-death review rule does not apply. Ordinary clinical, provenance, and safe-messaging reviews remain required.

Protocol deviations

Checks the monitoring protocol called for that the schedule did not perform. Each is recorded with its outcome and corrective action, never filled with an invented result.

VisitMeasureIntervalWhat happened
2026-05-18
Progress note 02 (C-CDA)
Liver tests (ALT) before eltrombopagBefore startingNo ALT is on record before eltrombopag started today; bilirubin was 0.6 mg/dL a week ago. A deviation from the protocol. Corrective action: ALT with the next blood draw
2026-05-18
Progress note 02 (C-CDA)
Viral serology before immunosuppression (hepatitis B, hepatitis C, HIV, CMV, EBV)At diagnosis, before immunosuppressionNo results are in this record before treatment started, a deviation from the protocol. Corrective action: flagged to hematology to send with the next blood draw
2026-05-18
Progress note 02 (C-CDA)
Antibacterial and antifungal prophylaxis while severely neutropenicWhile neutrophils are below 0.5 thousand per microliter, by local policyNeutrophils 0.4. Not prescribed today; the guideline leaves agent and threshold to local policy. Recorded as a gap for hematology to confirm; same-day fever plan in place
2026-06-08
Progress note 03 (C-CDA)
Weekly blood counts between visitsWeekly during the first months of treatmentNo counts are in this record between the consultation and today, so two weekly counts were missed, a deviation from the protocol. Platelets stayed above 15 and there was no bleeding or fever, so no harm resulted. Corrective action: weekly counts booked with the hematology day unit
2026-06-08
Progress note 03 (C-CDA)
Cyclosporine trough levelRegularly from the first weeks of treatment, to guide the doseNo trough level is in this record since cyclosporine started, a deviation from the protocol. The creatinine rise may reflect cyclosporine effect. Corrective action: trough requested from hematology with the next counts
2026-06-08
Progress note 03 (C-CDA)
Viral serology before immunosuppression (hepatitis B, hepatitis C, HIV, CMV, EBV)At diagnosis, before immunosuppressionStill not in this record; not sent with today's blood, a second miss. ALT is normal, with no sign of hepatitis. Corrective action: results requested from hematology
2026-06-08
Progress note 03 (C-CDA)
Antibacterial and antifungal prophylaxis while severely neutropenicWhile neutrophils are below 0.5 thousand per microliter, by local policyStill not prescribed; neutrophils 0.5, at the threshold, with no infection. Hematology to confirm under local policy
2026-06-29
Progress note 04 (C-CDA)
Weekly blood counts between visitsWeekly during the first months of treatmentAgain no counts are in this record between visits, a second deviation from the protocol. Counts are rising with no bleeding or infection, so no harm resulted. Corrective action: weekly counts confirmed with the hematology day unit
2026-06-29
Progress note 04 (C-CDA)
Cyclosporine trough levelRegularly from the first weeks of treatment, to guide the doseStill no trough level in this record, a second deviation from the protocol. The creatinine rise now warrants a dose review. Corrective action: hematology contacted today for a trough and dose review
2026-06-29
Progress note 04 (C-CDA)
Viral serology before immunosuppression (hepatitis B, hepatitis C, HIV, CMV, EBV)At diagnosis, before immunosuppressionStill not in this record. ALT remains normal. Corrective action: hematology asked again today
2026-06-29
Progress note 04 (C-CDA)
Pressure check after laser capsulotomyAfter the laserNo post-laser pressure reading is in this record. No pain, halos, or loss of vision, and reading has improved, so no harm is apparent. Corrective action: request the laser-day note from ophthalmology

Orders and referrals without results in the record

VisitTypeItemStatusDetail
2026-06-08
Progress note 03 (C-CDA)
ReferralComprehensive dilated eye examinationReferredOphthalmology appointment next week

Evidence to check

Retrospective claims (R)

ClaimStatementCertainty
CLM-0003Her bone marrow failure has been attributed to long exposure to radiation: the sanatorium director wrote that the marrow had probably been injured by a long accumulation of radiations, and a historian concludes that radiation exposure likely shortened her life.probable
CLM-0006Her cataracts are regarded as an early documented example of radiation cataract.probable

Sensitive claims

None.

Diagnoses not confirmed

None.

Notes to read

Every note in the record, with its type. All clinical content is synthetic.

Abnormal results

DateResultValueFlag
2026-05-11Hemoglobin7.2 g/dL (low)Low
2026-05-11White blood cell count1.9 10*3/uL (low)Low
2026-05-11Absolute neutrophil count0.4 10*3/uL (low)Low
2026-05-11Platelet count18 10*3/uL (low)Low
2026-05-11MCV104 fL (high)High
2026-05-11Absolute reticulocyte count14 10*3/uL (low)Low
2026-05-11Ferritin185 ng/mL (high)High
2026-05-18Hemoglobin8.9 g/dL (low)Low
2026-05-18White blood cell count1.8 10*3/uL (low)Low
2026-05-18Absolute neutrophil count0.4 10*3/uL (low)Low
2026-05-18Platelet count15 10*3/uL (low)Low
2026-05-18MCV101 fL (high)High
2026-05-18Absolute reticulocyte count12 10*3/uL (low)Low
2026-06-08Hemoglobin8.2 g/dL (low)Low
2026-06-08White blood cell count2 10*3/uL (low)Low
2026-06-08Absolute neutrophil count0.5 10*3/uL (low)Low
2026-06-08Platelet count21 10*3/uL (low)Low
2026-06-08MCV102 fL (high)High
2026-06-08Absolute reticulocyte count18 10*3/uL (low)Low
2026-06-08Glucose101 mg/dL (high)High
2026-06-29Hemoglobin8.9 g/dL (low)Low
2026-06-29White blood cell count2.4 10*3/uL (low)Low
2026-06-29Absolute neutrophil count0.8 10*3/uL (low)Low
2026-06-29Platelet count34 10*3/uL (low)Low
2026-06-29MCV101 fL (high)High